| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 25/05/22 | GSK | 15:41:00 | 25 May 2022 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 01/12/21 | GSK | 11:05:00 | 1 Dec 2021 | | GSK | Total Voting Rights | GSK plc | PRN |
| 21/04/17 | | 14:36:52 | 21 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 18:38:01 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 17:34:23 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 17:27:14 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 17:14:11 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 17:04:37 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 14:32:07 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 14:27:26 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 19/04/17 | | 14:21:11 | 19 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 18/04/17 | | 17:13:17 | 18 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 18/04/17 | | 10:16:15 | 18 Apr 2017 | | | GSK vaccine submission for shingles in Japan | GlaxoSmithKline PLC | RNS |
| 11/04/17 | | 18:26:11 | 11 Apr 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 11/04/17 | | 13:02:56 | 11 Apr 2017 | | | Change to financial reporting framework | GlaxoSmithKline PLC | RNS |
| 03/04/17 | | 12:26:50 | 3 Apr 2017 | | | Total Voting Rights | GlaxoSmithKline PLC | RNS |
| 31/03/17 | | 12:04:02 | 31 Mar 2017 | | | Phase 3 study start of mepolizumab in severe HES | GlaxoSmithKline PLC | RNS |
| 30/03/17 | | 14:00:03 | 30 Mar 2017 | | | Notice of AGM | GlaxoSmithKline PLC | RNS |
| 23/03/17 | | 16:55:22 | 23 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 21/03/17 | | 12:19:49 | 21 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 20/03/17 | | 07:00:05 | 20 Mar 2017 | | | GSK 2016 Form 20F | GlaxoSmithKline PLC | RNS |
| 16/03/17 | | 16:13:53 | 16 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 15/03/17 | | 17:07:57 | 15 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/03/17 | | 13:00:12 | 14 Mar 2017 | | | Publication of 2016 Annual Financial Report | GlaxoSmithKline PLC | RNS |
| 10/03/17 | | 16:10:55 | 10 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 08/03/17 | | 16:26:35 | 8 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 06/03/17 | | 16:51:32 | 6 Mar 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 06/03/17 | | 14:49:46 | 6 Mar 2017 | | | GSK's MUSCA study results on Nucala (mepolizumab) | GlaxoSmithKline PLC | RNS |
| 01/03/17 | | 10:06:39 | 1 Mar 2017 | | | Total Voting Rights | GlaxoSmithKline PLC | RNS |
| 23/02/17 | | 15:07:05 | 23 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 23/02/17 | | 14:57:22 | 23 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 23/02/17 | | 09:59:46 | 23 Feb 2017 | | | Positive results for Relvar Ellipta Lung Study | GlaxoSmithKline PLC | RNS |
| 22/02/17 | | 13:58:35 | 22 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 21/02/17 | | 17:14:30 | 21 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 20/02/17 | | 15:55:56 | 20 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 20/02/17 | | 14:12:40 | 20 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/02/17 | | 15:58:18 | 17 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/02/17 | | 15:57:02 | 17 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 17/02/17 | | 15:55:10 | 17 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 15/02/17 | | 17:15:34 | 15 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/02/17 | | 12:43:24 | 14 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/02/17 | | 09:49:04 | 14 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 14/02/17 | | 07:00:05 | 14 Feb 2017 | | | ViiV Phase III results Dolutegravir & Rilpivirine | GlaxoSmithKline PLC | RNS |
| 13/02/17 | | 17:04:31 | 13 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 10/02/17 | | 15:47:36 | 10 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 10/02/17 | | 11:10:06 | 10 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 10/02/17 | | 08:42:38 | 10 Feb 2017 | | | Blocklisting Application | GlaxoSmithKline PLC | RNS |
| 09/02/17 | | 17:32:22 | 9 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
| 09/02/17 | | 13:42:15 | 9 Feb 2017 | | | Director/PDMR Shareholding | GlaxoSmithKline PLC | RNS |
